Can I Take St. John's Wort with Losartan?

How Losartan Works in Your Body

Losartan is an angiotensin II receptor blocker (ARB) prescribed for hypertension, heart failure, and diabetic nephropathy. It blocks the AT1 receptor, reducing vasoconstriction and aldosterone release. But losartan itself is actually a prodrug.

The Prodrug Conversion Step

After oral dosing, hepatic cytochrome P450 enzymes convert losartan into its active metabolite, EXP-3174. This metabolite is 10 to 40 times more potent at blocking the AT1 receptor than the parent compound [1]. CYP2C9 handles roughly 80% of that conversion, with CYP3A4 contributing a secondary pathway [2]. Anything that alters CYP2C9 or CYP3A4 activity can shift how much EXP-3174 your liver produces and how quickly both compounds are cleared.

Why This Matters for Interactions

Because losartan depends on enzymatic activation, enzyme inducers create a paradox. Faster CYP2C9 activity could theoretically increase EXP-3174 formation. In practice, induction also accelerates the clearance of EXP-3174 itself, and P-glycoprotein induction reduces intestinal absorption of the parent drug [3]. The net clinical effect of broad-spectrum enzyme induction is typically a reduction in total drug exposure and weaker blood pressure control.

What St. John's Wort Does to Drug Metabolism

St. John's Wort is one of the most pharmacokinetically new herbal supplements available without a prescription. Its active constituent hyperforin activates the pregnane X receptor (PXR), which upregulates transcription of multiple cytochrome P450 enzymes and the efflux transporter P-glycoprotein [4].

Enzymes and Transporters Affected

A landmark study by Markowitz et al. Demonstrated that 14 days of St. John's Wort supplementation (900 mg/day) significantly induced CYP3A4 activity as measured by the midazolam clearance probe [5]. Separate probe-drug studies have confirmed induction of CYP2C9, CYP1A2, and CYP2C19 [6]. P-glycoprotein induction was documented using digoxin pharmacokinetics, showing a 25% reduction in steady-state digoxin AUC after 10 days of co-administration [7].

Time Course of Induction

Enzyme induction is not immediate. PXR-mediated transcriptional upregulation takes 7 to 14 days to reach full effect [4]. This means blood pressure might remain stable for the first week of overlap, then gradually rise. After discontinuing St. John's Wort, enzyme activity returns to baseline over another 1 to 2 weeks. That reversal period carries its own risk: losartan concentrations may temporarily increase, potentially causing hypotension or dizziness.

The Losartan and St. John's Wort Interaction Explained

No randomized controlled trial has tested this exact drug-herb pair in a head-to-head pharmacokinetic study. The interaction is predicted from the established metabolic pathways of losartan and the documented enzyme-induction profile of St. John's Wort.

Pharmacokinetic Mechanism

St. John's Wort induces CYP2C9, CYP3A4, and P-glycoprotein simultaneously. For losartan, this creates three compounding effects. First, increased P-glycoprotein expression in the gut wall reduces oral bioavailability of losartan [3]. Second, accelerated hepatic CYP2C9 and CYP3A4 activity increases first-pass metabolism. Third, the active metabolite EXP-3174 is itself cleared more rapidly. The Lexicomp and Natural Medicines interaction databases classify this combination as a moderate interaction requiring monitoring [8].

Pharmacodynamic Considerations

St. John's Wort also has mild serotonergic and noradrenergic reuptake inhibition properties. While these do not directly oppose losartan's mechanism at the AT1 receptor, noradrenergic stimulation can raise sympathetic tone and slightly increase blood pressure in some patients [9]. This pharmacodynamic effect is minor compared to the pharmacokinetic interaction, but it works in the same unfavorable direction.

What the Evidence Base Shows

A 2009 systematic review by Borrelli and Izzo catalogued 147 documented herb-drug interactions involving St. John's Wort, making it the most interaction-prone herbal supplement studied [10]. While losartan was not individually evaluated in a clinical trial within that review, multiple drugs sharing CYP2C9 and CYP3A4 metabolism (including warfarin, whose S-enantiomer is a CYP2C9 substrate) showed clinically meaningful reductions in plasma concentration [10]. A 2014 pharmacokinetic modeling study estimated that concomitant St. John's Wort could reduce losartan AUC by 30 to 50% based on CYP2C9 induction magnitude observed with the probe substrate tolbutamide [6].

Clinical Risks of the Combination

Blood pressure that creeps upward over two weeks may not trigger obvious symptoms until it reaches dangerous levels.

Uncontrolled Hypertension

The primary risk is loss of blood pressure control. A patient stable on losartan 100 mg daily could experience a functional dose reduction equivalent to 50 to 70 mg if CYP2C9 induction reaches its full potential [6]. For context, the LIFE trial (N=9,193) demonstrated that each 1 mmHg increase in systolic blood pressure correlated with a measurable increase in stroke risk among hypertensive patients with left ventricular hypertrophy [11]. Undetected blood pressure elevation for even a few weeks carries cardiovascular risk.

Diabetic Nephropathy Progression

Losartan holds a specific FDA indication for diabetic nephropathy based on the RENAAL trial (N=1,513), which showed a 16% reduction in the primary composite endpoint of doubling of serum creatinine, end-stage renal disease, or death [12]. Reduced losartan exposure from enzyme induction could compromise this renal protective effect in patients who depend on consistent ARB blockade to slow kidney disease.

Rebound Risk After Stopping St. John's Wort

Patients who stop St. John's Wort without medical guidance face the opposite problem. As CYP2C9 and CYP3A4 activity normalizes over 1 to 2 weeks, losartan and EXP-3174 levels rise back toward their uninduced concentrations [4]. If the prescriber had increased the losartan dose to compensate for the interaction, the patient could experience symptomatic hypotension, dizziness, or acute kidney injury from excessive AT1 blockade.

Monitoring If You Are Already Taking Both

If you have been combining these agents, abrupt discontinuation of either one without guidance is not recommended.

Home Blood Pressure Protocol

Check blood pressure at home twice daily (morning and evening) using a validated upper-arm cuff. Record readings for at least 14 consecutive days. The American Heart Association defines home hypertension as an average above 135/85 mmHg [13]. Share these readings with your prescriber at your next visit or sooner if readings exceed 150/95 mmHg on two consecutive measurements.

Lab Work to Consider

Your physician may order a basic metabolic panel to check serum creatinine and potassium, particularly if you take losartan for diabetic nephropathy. CYP2C9 genotyping is available but rarely necessary for this scenario. Poor metabolizers (CYP2C9 *2/*3 or *3/*3 genotypes, found in approximately 1 to 3% of Caucasian populations) produce less EXP-3174 at baseline and may experience a different net interaction effect [2].

Tapering Strategy

If the decision is made to discontinue St. John's Wort, your prescriber should monitor blood pressure weekly for two to three weeks. No dose adjustment of losartan is typically needed during this period as long as blood pressure stays within the target range. Abrupt St. John's Wort cessation is pharmacokinetically acceptable (the induction resolves gradually), but mood symptoms may recur and should be addressed with an alternative treatment plan.

Safer Alternatives for Mood Support While on Losartan

Patients taking losartan for blood pressure or renal protection have several options for managing mild-to-moderate depression or anxiety without introducing CYP-inducing herbs.

Non-Pharmacologic Approaches

Cognitive behavioral therapy (CBT) has a strong evidence base for mild-to-moderate depression, with response rates comparable to SSRIs in the STAR*D trial follow-up analyses [14]. Regular aerobic exercise (150 minutes per week at moderate intensity) carries a separate cardiovascular benefit and has demonstrated antidepressant effects in multiple meta-analyses [15].

Prescription Medications With Low Interaction Risk

SSRIs such as sertraline carry a low interaction potential with losartan. Sertraline is a weak CYP2C9 inhibitor at standard doses (50 to 100 mg), which could modestly increase losartan and EXP-3174 exposure, but this effect is rarely clinically significant [16]. Escitalopram has minimal CYP inhibition overall and is another reasonable option. Your prescriber can select an antidepressant based on your full medication list and comorbidity profile.

Supplements With Fewer Interaction Concerns

Magnesium glycinate (200 to 400 mg daily) has shown modest anxiolytic effects in a 2017 systematic review (N=18 studies) without documented CYP enzyme induction [17]. Omega-3 fatty acids (EPA-predominant formulations at 1 to 2 g daily) showed a small but statistically significant antidepressant effect in a 2019 meta-analysis of 26 RCTs (N=2,160) [18]. Neither supplement carries known pharmacokinetic interactions with losartan.

What Prescribers Should Know

Clinicians managing patients on losartan should screen for St. John's Wort use at every medication reconciliation. A 2017 survey published in the Journal of General Internal Medicine found that 33% of patients using herbal supplements did not disclose them to their physician [19].

Dose-Separation Does Not Work Here

Unlike antacid-drug interactions that can be managed with staggered dosing, CYP enzyme induction is a systemic, time-dependent effect. Taking losartan in the morning and St. John's Wort at night does not reduce the interaction. The induced enzymes remain upregulated around the clock [4].

CYP2C9 Genotype Adds Complexity

Approximately 35% of the population carries at least one reduced-function CYP2C9 allele [2]. In these patients, baseline conversion of losartan to EXP-3174 is already impaired. The clinical consequence of St. John's Wort induction in a CYP2C9 poor metabolizer is unpredictable and could paradoxically normalize their metabolic ratio while increasing clearance of the parent drug. Genotype-informed management is reasonable if unexplained blood pressure variability occurs during herbal co-administration.

The 2023 ACC/AHA hypertension guideline update recommends documenting all supplement use as part of the standard hypertension evaluation and specifically flags St. John's Wort as a supplement associated with drug interactions relevant to cardiovascular pharmacotherapy [20].